Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial (Q40754073)
Jump to navigation
Jump to search
scientific article published on 6 July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial |
scientific article published on 6 July 2015 |
Statements
1 reference
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial (English)
1 reference
Yi-Long Wu
1 reference
Kazuhiko Nakagawa
1 reference
Sang-We Kim
1 reference
Jin-Ji Yang
1 reference
Myung-Ju Ahn
1 reference
Jie Wang
1 reference
James Chih-Hsin Yang
1 reference
You Lu
1 reference
Shinji Atagi
1 reference
Santiago Ponce
1 reference
Dae Ho Lee
1 reference
Yunpeng Liu
1 reference
Kiyotaka Yoh
1 reference
Jian-Ying Zhou
1 reference
Xiaojin Shi
1 reference
Alan Webster
1 reference
Haiyi Jiang
1 reference
Tony S K Mok
1 reference
6 July 2015
1 reference
1 reference
Identifiers
1 reference